Company: ABUS
Filing Date: 2025-05-14
Form Type: 10-Q
Source: 0001447028-25-000099
Chunk: 13

Company: Arbutus Biopharma Corp
Filing Date: 2025-05-14
Form: 10-Q
Item: Part I, Item 1
Chunk 13
---
 licenses$1,316 $939 Non-cash royalty revenue448 593 Total Revenue1,764 1,532 Operating expenses Research and development8,959 15,403 General and administrative5,832 5,312 Change in fair value of contingent consideration299 180 Restructuring12,373 — Total operating expenses27,463 20,895 Loss from operations(25,699)(19,363)Other incomeInterest income1,197 1,545 Interest expense(28)(44)Foreign exchange gain/(loss)4 (13)Total other income1,173 1,488 Net loss$(24,526)$(17,875)Loss per share  Basic and diluted$(0.13)$(0.10)Weighted average number of common shares  Basic and diluted190,707,085 175,625,552 Comprehensive lossUnrealized gain on available-for-sale securities$(31)$50 Comprehensive loss$(24,557)$(17,825)

See accompanying notes to the condensed consolidated financial statements.

2

ARBUTUS BIOPHARMA CORPORATION

Condensed Consolidated Statements of Stockholders’ Equity

(Unaudited)

(In thousands of U.S. Dollars, except share amounts)

Common Shares Number of SharesShare CapitalAdditional Paid-In CapitalDeficitAccumulated Other Comprehensive LossTotal Stockholders' EquityBalance December 31, 2024189,963,492 $1,410,025 $82,048 $(1,346,572)$(48,135)$97,366 Stock-based compensation expense— — 3,564 — — 3,564 Issuance of common shares pursuant to exercise of options892,857 4,616 (1,963)— — 2,653 Issuance of common shares pursuant to ESPP44,541 173 (42)— — 131 Issuance of common shares upon vesting of RSUs580,584 1,518 (1,518)— — — Unrealized gain on available-for-sale securities— — — — (31)(31)Net loss— — — (24,526)— (24,526)Balance March 31, 2025191,481,474 $1,416,332 $82,089 $(1,